Pharmacological Properties of Sulfonamide Derivatives, New Inhibitors of Carbonic Anhydrase

Selective blocking of individual isoforms of carbonic anhydrase (CA) is now one of the main directions in the development of its inhibitors. The new 1,2,4-oxadiazole-containing sulfonamides B12 and B13 predominantly block CA II and CA IX. The study of acute toxicity of B12 and B13 showed their safet...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Bulletin of experimental biology and medicine Ročník 175; číslo 2; s. 205 - 209
Hlavní autori: Khokhlov, A. L., Shetnev, A. A., Korsakov, M. K., Fedorov, V. N., Tyushina, A. N., Volkhin, N. N., Vdovichenko, V. P.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: New York Springer US 01.06.2023
Springer
Springer Nature B.V
Predmet:
Acute toxicity
Analysis
Animals
Antibiotics
Antidepressants
Antigens, Neoplasm
Biomedical and Life Sciences
Biomedicine
Brinzolamide
Carbon dioxide
Carbonic Anhydrase Inhibitors - pharmacology
Carbonic anhydrases
Carbonic Anhydrases - metabolism
Cell Biology
Drugs
Enzymes
Glaucoma
Internal Medicine
Isoforms
Laboratory animals
Laboratory Medicine
Medical practices
Pathology
Pedagogy
Pharmaceuticals
Physiology
Protein Isoforms
Rabbits
Respiration
Structure-Activity Relationship
Sulfonamides
Sulfonamides - pharmacology
Toxicology
carbonic anhydrases
sulfonamides
carbonic anhydrase inhibitors
intraocular pressure
ISSN:0007-4888, 1573-8221, 1573-8221
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Selective blocking of individual isoforms of carbonic anhydrase (CA) is now one of the main directions in the development of its inhibitors. The new 1,2,4-oxadiazole-containing sulfonamides B12 and B13 predominantly block CA II and CA IX. The study of acute toxicity of B12 and B13 showed their safety. Substance B13 caused a relatively short-term, but rapid (within 30 min) decrease in the intraocular pressure in rabbits, which indicates the promise of its use for the emergency decrease in the intraocular pressure in medical practice. Analysis of the effects of sulfonamides on the functions of CNS showed that compound B12 probably exhibit tranquilizing activity; B13 is promising for the creation of drugs that have an antidepressant effect and at the same time increase the mental and physical performance.
AbstractList Selective blocking of individual isoforms of carbonic anhydrase (CA) is now one of the main directions in the development of its inhibitors. The new 1,2,4-oxadiazole-containing sulfonamides B12 and B13 predominantly block CA II and CA IX. The study of acute toxicity of B12 and B13 showed their safety. Substance B13 caused a relatively short-term, but rapid (within 30 min) decrease in the intraocular pressure in rabbits, which indicates the promise of its use for the emergency decrease in the intraocular pressure in medical practice. Analysis of the effects of sulfonamides on the functions of CNS showed that compound B12 probably exhibit tranquilizing activity; B13 is promising for the creation of drugs that have an antidepressant effect and at the same time increase the mental and physical performance.Selective blocking of individual isoforms of carbonic anhydrase (CA) is now one of the main directions in the development of its inhibitors. The new 1,2,4-oxadiazole-containing sulfonamides B12 and B13 predominantly block CA II and CA IX. The study of acute toxicity of B12 and B13 showed their safety. Substance B13 caused a relatively short-term, but rapid (within 30 min) decrease in the intraocular pressure in rabbits, which indicates the promise of its use for the emergency decrease in the intraocular pressure in medical practice. Analysis of the effects of sulfonamides on the functions of CNS showed that compound B12 probably exhibit tranquilizing activity; B13 is promising for the creation of drugs that have an antidepressant effect and at the same time increase the mental and physical performance.
Selective blocking of individual isoforms of carbonic anhydrase (CA) is now one of the main directions in the development of its inhibitors. The new 1,2,4-oxadiazole-containing sulfonamides B12 and B13 predominantly block CA II and CA IX. The study of acute toxicity of B12 and B13 showed their safety. Substance B13 caused a relatively short-term, but rapid (within 30 min) decrease in the intraocular pressure in rabbits, which indicates the promise of its use for the emergency decrease in the intraocular pressure in medical practice. Analysis of the effects of sulfonamides on the functions of CNS showed that compound B12 probably exhibit tranquilizing activity; B13 is promising for the creation of drugs that have an antidepressant effect and at the same time increase the mental and physical performance.
Selective blocking of individual isoforms of carbonic anhydrase (CA) is now one of the main directions in the development of its inhibitors. The new 1,2,4-oxadiazole-containing sulfonamides B12 and B13 predominantly block CA II and CA IX. The study of acute toxicity of B12 and B13 showed their safety. Substance B13 caused a relatively short-term, but rapid (within 30 min) decrease in the intraocular pressure in rabbits, which indicates the promise of its use for the emergency decrease in the intraocular pressure in medical practice. Analysis of the effects of sulfonamides on the functions of CNS showed that compound B12 probably exhibit tranquilizing activity; B13 is promising for the creation of drugs that have an antidepressant effect and at the same time increase the mental and physical performance. Key Words: carbonic anhydrases; carbonic anhydrase inhibitors; sulfonamides; intraocular pressure
Audience Academic
Author Korsakov, M. K.
Tyushina, A. N.
Volkhin, N. N.
Shetnev, A. A.
Fedorov, V. N.
Vdovichenko, V. P.
Khokhlov, A. L.
Author_xml – sequence: 1
  givenname: A. L.
  surname: Khokhlov
  fullname: Khokhlov, A. L.
  organization: Yaroslavl State Medical University, Ministry of Health of the Russian Federation
– sequence: 2
  givenname: A. A.
  surname: Shetnev
  fullname: Shetnev, A. A.
  organization: M. V. Dorogov Center of Pharmaceutical Technology Transfer, K. D. Ushinsky Yaroslavl State Pedagogical University
– sequence: 3
  givenname: M. K.
  surname: Korsakov
  fullname: Korsakov, M. K.
  email: mkkors@mail.ru
  organization: M. V. Dorogov Center of Pharmaceutical Technology Transfer, K. D. Ushinsky Yaroslavl State Pedagogical University
– sequence: 4
  givenname: V. N.
  surname: Fedorov
  fullname: Fedorov, V. N.
  organization: M. V. Dorogov Center of Pharmaceutical Technology Transfer, K. D. Ushinsky Yaroslavl State Pedagogical University
– sequence: 5
  givenname: A. N.
  surname: Tyushina
  fullname: Tyushina, A. N.
  organization: M. V. Dorogov Center of Pharmaceutical Technology Transfer, K. D. Ushinsky Yaroslavl State Pedagogical University
– sequence: 6
  givenname: N. N.
  surname: Volkhin
  fullname: Volkhin, N. N.
  organization: M. V. Dorogov Center of Pharmaceutical Technology Transfer, K. D. Ushinsky Yaroslavl State Pedagogical University
– sequence: 7
  givenname: V. P.
  surname: Vdovichenko
  fullname: Vdovichenko, V. P.
  organization: M. V. Dorogov Center of Pharmaceutical Technology Transfer, K. D. Ushinsky Yaroslavl State Pedagogical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37464193$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1q3DAUhUVJaSZpX6CLYiiULupUv5a8HKZ_gdAG2q66EJJ9PVawpYlkZ8jbV5NJSBNK0EJIfN_hIp0jdOCDB4ReE3xCMJYfE8GCyBJTVmKhmCi3z9CCCMlKRSk5QAucqZIrpQ7RUUoXuyOuyAt0yCSvOKnZAv05700cTROGsHaNGYrzGDYQJwepCF3xcx664M3oWig-QXRXZnJXkD4U32FbnPreWTeFeIOuTLTBu6ZY-v66jSbBS_S8M0OCV7f7Mfr95fOv1bfy7MfX09XyrGy4ZFNZ10qZGhNaGyyoFbyl1hjBAJhsVYUVMdYw1QoCrONWWNlxbCQFam3DqGLH6P0-dxPD5Qxp0qNLDQyD8RDmpDNSS06UIhl9-wi9CHP0ebpMcVrVtaj4PbU2A2jnuzBF0-xC9VJWggssqypTJ_-h8mphdE3-qs7l-wfCu3-EHsww9SkM8-SCTw_BN7dTznaEVm-iG0281nfflgG1B5oYUorQ6cZNZpeTR3CDJljvGqL3DdG5IfqmIXqbVfpIvUt_UmJ7KWXYryHeP9sT1l8grstC
CitedBy_id crossref_primary_10_30895_1991_2919_2025_743
crossref_primary_10_3389_fchem_2025_1606848
crossref_primary_10_30895_1991_2919_2025_697
Cites_doi 10.3109/14756366.2015.1122001
10.18008/1816-5095-2020-4-676-682
10.1517/13543776.2012.649006
10.1080/13543776.2018.1519023
10.18008/1816-5095-2020-3S-542-549
10.1016/j.bioorg.2019.103557
10.1017/CBO9781139344319
10.1016/j.ejmech.2019.02.044
10.1124/jpet.110.167270
ContentType Journal Article
Copyright Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2023. Springer Science+Business Media, LLC, part of Springer Nature.
COPYRIGHT 2023 Springer
Copyright_xml – notice: Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2023. Springer Science+Business Media, LLC, part of Springer Nature.
– notice: COPYRIGHT 2023 Springer
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
8AO
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s10517-023-05835-w
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
ProQuest Biological Science
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



ProQuest Central Student
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1573-8221
EndPage 209
ExternalDocumentID A765450766
37464193
10_1007_s10517_023_05835_w
Genre Journal Article
GroupedDBID ---
-4W
-56
-5G
-BR
-EM
-Y2
-~C
-~X
.86
.GJ
.VR
06C
06D
0R~
0VY
1N0
1SB
2.D
23N
28-
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3SX
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5VS
642
67N
67Z
6NX
7X7
88A
88E
8AO
8FE
8FH
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABQBU
ABQSL
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACSNA
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYPR
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFFNX
AFGCZ
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBNVY
BBWZM
BDATZ
BENPR
BGNMA
BHPHI
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
EN4
EPAXT
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GXS
HCIFZ
HF~
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
IAO
IHE
IHR
IHW
IJ-
IKXTQ
INH
INR
ITC
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAK
LK8
LLZTM
M0L
M1P
M4Y
M7P
MA-
MK0
N2Q
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
PF0
PKN
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RNI
RNS
ROL
RPX
RSV
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S3A
S3B
SAP
SBL
SBY
SCLPG
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
STPWE
SV3
SZN
T13
T16
TEORI
TSG
TSK
TSV
TUC
TUS
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK6
WK8
XU3
YLTOR
Z7U
Z82
Z87
Z8O
Z8V
Z91
ZOVNA
ZXP
~A9
~EX
~KM
AAPKM
AAYXX
ABDBE
ABFSG
ABRTQ
ACSTC
ADHKG
AEZWR
AFDZB
AFFHD
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
ID FETCH-LOGICAL-c473t-9988a90129a052b54d2baa53ee37d86081aba38d51e3f4b5b7f40a72e2bbc3283
IEDL.DBID RSV
ISICitedReferencesCount 1
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001031541700007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0007-4888
1573-8221
IngestDate Thu Oct 02 06:37:43 EDT 2025
Sat Nov 08 14:41:58 EST 2025
Sat Nov 29 14:02:27 EST 2025
Sat Nov 29 10:39:14 EST 2025
Thu May 22 21:24:27 EDT 2025
Thu Apr 03 07:09:55 EDT 2025
Sat Nov 29 04:01:04 EST 2025
Tue Nov 18 22:25:18 EST 2025
Fri Feb 21 02:42:43 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords carbonic anhydrases
sulfonamides
carbonic anhydrase inhibitors
intraocular pressure
Language English
License 2023. Springer Science+Business Media, LLC, part of Springer Nature.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c473t-9988a90129a052b54d2baa53ee37d86081aba38d51e3f4b5b7f40a72e2bbc3283
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 37464193
PQID 2842699564
PQPubID 47742
PageCount 5
ParticipantIDs proquest_miscellaneous_2839741881
proquest_journals_2842699564
gale_infotracmisc_A765450766
gale_infotracacademiconefile_A765450766
gale_healthsolutions_A765450766
pubmed_primary_37464193
crossref_citationtrail_10_1007_s10517_023_05835_w
crossref_primary_10_1007_s10517_023_05835_w
springer_journals_10_1007_s10517_023_05835_w
PublicationCentury 2000
PublicationDate 20230600
2023-06-00
2023-Jun
20230601
PublicationDateYYYYMMDD 2023-06-01
PublicationDate_xml – month: 6
  year: 2023
  text: 20230600
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: United States
PublicationTitle Bulletin of experimental biology and medicine
PublicationTitleAbbrev Bull Exp Biol Med
PublicationTitleAlternate Bull Exp Biol Med
PublicationYear 2023
Publisher Springer US
Springer
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer
– name: Springer Nature B.V
References Ghorai S, Pulya S, Ghosh K, Panda P, Ghosh B, Gayen S. Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents. Bioorg. Chem. 2020;95:103557. doi: https://doi.org/10.1016/j.bioorg.2019.103557
CartaFSupuranCTScozzafavaANovel therapies for glaucoma: a patent review 2007–2011Expert Opin. Ther. Pat.201222179881:CAS:528:DC%2BC38Xjs1Cqug%3D%3D10.1517/13543776.2012.64900622191414
SupuranCTApplications of carbonic anhydrases inhibitors in renal and central nervous system diseasesExpert Opin. Ther. Pat.201828107137211:CAS:528:DC%2BC1cXhs1Olt77I10.1080/13543776.2018.151902330175635
CianchiFVinciMCSupuranCTPeruzziBDe GiuliPFasolisGPerigliGPastorekovaSPapucciLPiniAMasiniEPuccettiLSelective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cellsJ. Pharmacol. Exp. Ther.201033437107191:CAS:528:DC%2BC3cXhtFyksL7K10.1124/jpet.110.16727020519553
Manual for Preclinical Studies of New Pharmacological Substances. Part I, Mironov AN, ed. Moscow, 2012. Russian.
KuryshevaNICarbonic anhydrase inhibitors in the treatment of glaucomaReview. Part II. Oftalmologiya.202017467668210.18008/1816-5095-2020-4-676-682
Kurysheva NI. Carbonic anhydrase inhibitors in the treatment of glaucoma. Review. Part I. Oftalmologiya. 2020;17(S3):542-549. Russian. doi: https://doi.org/10.18008/1816-5095-2020-3S-542-549
SupuranCTHow many carbonic anhydrase inhibition mechanisms exist?J. Enzyme Inhib. Med. Chem.20163133453601:CAS:528:DC%2BC2MXhvFGms7bE10.3109/14756366.2015.112200126619898
KrasavinMShetnevABaykovSKalininSNocentiniASharoykoVPoliGTuccinardiTKorsakovMTennikovaTBSupuranCTPyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell linesEur. J. Med. Chem.20191683013141:CAS:528:DC%2BC1MXktFOktr4%3D10.1016/j.ejmech.2019.02.04430826507
Bate ST, Clark RA. The Design and Statistical Analysis of Animal Experiments. Cambridge, 2014.
5835_CR1
F Carta (5835_CR2) 2012; 22
M Krasavin (5835_CR7) 2019; 168
CT Supuran (5835_CR5) 2018; 28
5835_CR6
5835_CR9
CT Supuran (5835_CR3) 2016; 31
F Cianchi (5835_CR8) 2010; 334
NI Kurysheva (5835_CR4) 2020; 17
5835_CR10
References_xml – reference: Ghorai S, Pulya S, Ghosh K, Panda P, Ghosh B, Gayen S. Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents. Bioorg. Chem. 2020;95:103557. doi: https://doi.org/10.1016/j.bioorg.2019.103557
– reference: Kurysheva NI. Carbonic anhydrase inhibitors in the treatment of glaucoma. Review. Part I. Oftalmologiya. 2020;17(S3):542-549. Russian. doi: https://doi.org/10.18008/1816-5095-2020-3S-542-549
– reference: CianchiFVinciMCSupuranCTPeruzziBDe GiuliPFasolisGPerigliGPastorekovaSPapucciLPiniAMasiniEPuccettiLSelective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cellsJ. Pharmacol. Exp. Ther.201033437107191:CAS:528:DC%2BC3cXhtFyksL7K10.1124/jpet.110.16727020519553
– reference: SupuranCTApplications of carbonic anhydrases inhibitors in renal and central nervous system diseasesExpert Opin. Ther. Pat.201828107137211:CAS:528:DC%2BC1cXhs1Olt77I10.1080/13543776.2018.151902330175635
– reference: KuryshevaNICarbonic anhydrase inhibitors in the treatment of glaucomaReview. Part II. Oftalmologiya.202017467668210.18008/1816-5095-2020-4-676-682
– reference: Bate ST, Clark RA. The Design and Statistical Analysis of Animal Experiments. Cambridge, 2014.
– reference: CartaFSupuranCTScozzafavaANovel therapies for glaucoma: a patent review 2007–2011Expert Opin. Ther. Pat.201222179881:CAS:528:DC%2BC38Xjs1Cqug%3D%3D10.1517/13543776.2012.64900622191414
– reference: KrasavinMShetnevABaykovSKalininSNocentiniASharoykoVPoliGTuccinardiTKorsakovMTennikovaTBSupuranCTPyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell linesEur. J. Med. Chem.20191683013141:CAS:528:DC%2BC1MXktFOktr4%3D10.1016/j.ejmech.2019.02.04430826507
– reference: SupuranCTHow many carbonic anhydrase inhibition mechanisms exist?J. Enzyme Inhib. Med. Chem.20163133453601:CAS:528:DC%2BC2MXhvFGms7bE10.3109/14756366.2015.112200126619898
– reference: Manual for Preclinical Studies of New Pharmacological Substances. Part I, Mironov AN, ed. Moscow, 2012. Russian.
– volume: 31
  start-page: 345
  issue: 3
  year: 2016
  ident: 5835_CR3
  publication-title: J. Enzyme Inhib. Med. Chem.
  doi: 10.3109/14756366.2015.1122001
– volume: 17
  start-page: 676
  issue: 4
  year: 2020
  ident: 5835_CR4
  publication-title: Review. Part II. Oftalmologiya.
  doi: 10.18008/1816-5095-2020-4-676-682
– volume: 22
  start-page: 79
  issue: 1
  year: 2012
  ident: 5835_CR2
  publication-title: Expert Opin. Ther. Pat.
  doi: 10.1517/13543776.2012.649006
– volume: 28
  start-page: 713
  issue: 10
  year: 2018
  ident: 5835_CR5
  publication-title: Expert Opin. Ther. Pat.
  doi: 10.1080/13543776.2018.1519023
– ident: 5835_CR1
  doi: 10.18008/1816-5095-2020-3S-542-549
– ident: 5835_CR6
  doi: 10.1016/j.bioorg.2019.103557
– ident: 5835_CR10
  doi: 10.1017/CBO9781139344319
– volume: 168
  start-page: 301
  year: 2019
  ident: 5835_CR7
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2019.02.044
– volume: 334
  start-page: 710
  issue: 3
  year: 2010
  ident: 5835_CR8
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.110.167270
– ident: 5835_CR9
SSID ssj0007061
Score 2.2908933
Snippet Selective blocking of individual isoforms of carbonic anhydrase (CA) is now one of the main directions in the development of its inhibitors. The new...
SourceID proquest
gale
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 205
SubjectTerms Acute toxicity
Analysis
Animals
Antibiotics
Antidepressants
Antigens, Neoplasm
Biomedical and Life Sciences
Biomedicine
Brinzolamide
Carbon dioxide
Carbonic Anhydrase Inhibitors - pharmacology
Carbonic anhydrases
Carbonic Anhydrases - metabolism
Cell Biology
Drugs
Enzymes
Glaucoma
Internal Medicine
Isoforms
Laboratory animals
Laboratory Medicine
Medical practices
Pathology
Pedagogy
Pharmaceuticals
Physiology
Protein Isoforms
Rabbits
Respiration
Structure-Activity Relationship
Sulfonamides
Sulfonamides - pharmacology
Toxicology
SummonAdditionalLinks – databaseName: ProQuest Biological Science
  dbid: M7P
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BgYoLj1IgUCBISByoRRLbcXJCq0IFB6qVAKkSh8h2bHWlKmmzu63675lJvFm2Er1w9mQ31jwz9nwfwDtvfYZlgmIe0zsTsi5ZmSnNBLcYKAXm6LTuySbU0VFxfFxOQ8NtHq5VrmJiH6jr1lKP_COG0SynMUzx6eycEWsUna4GCo3bcIdQEnh_dW86RmKV5IExTzE01CIMzYTROYnxGTMWSyS95uVGYroenv_KT9cOTPs8dPjwf3fwCB6ECjSeDCbzGG65ZgfuDZyUVzuw_T2ctj-B39M1rjXpMp5S574jCNa49fGP5alvic--dvFnNOSLHkN8vh9j4Iy_NSczMyMqHxI90J0hDN540pxc1R1mzl34dfjl58FXFsgYmBWKLxh-lhW6pLaVTmRmpKgzo7XkznFVFzlWFtpoXtQyddwLI43yItEqc5kxlmMR8xS2mrZxzyGuE106lxgvay8krmHJYLmw-HXllTJZBOlKE5UNSOVEmHFarTGWSXsVaq_qtVddRvBhfOZswOm4UfoNKbgaZk1HJ68mKseKMlF5HsH7XoLcHP_b6jCtgDsgwKwNyb0NSXRPu7m8soYqhId5tTaFCN6Oy_QkXXlrXLskGSwVRVoUaQTPBuMbd8aVyAWW3hHsr6xx_eP_3vaLm9_lJdzPeoegHtMebC26pXsFd-3FYjbvXveu9Qe5ByXD
  priority: 102
  providerName: ProQuest
Title Pharmacological Properties of Sulfonamide Derivatives, New Inhibitors of Carbonic Anhydrase
URI https://link.springer.com/article/10.1007/s10517-023-05835-w
https://www.ncbi.nlm.nih.gov/pubmed/37464193
https://www.proquest.com/docview/2842699564
https://www.proquest.com/docview/2839741881
Volume 175
WOSCitedRecordID wos001031541700007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 1573-8221
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0007061
  issn: 0007-4888
  databaseCode: M7P
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection (ProQuest)
  customDbUrl:
  eissn: 1573-8221
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0007061
  issn: 0007-4888
  databaseCode: 7X7
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1573-8221
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0007061
  issn: 0007-4888
  databaseCode: BENPR
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: Springer Nature - Connect here FIRST to enable access
  customDbUrl:
  eissn: 1573-8221
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0007061
  issn: 0007-4888
  databaseCode: RSV
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7RFhAXHgXaQFmChMSBWsrDjpPjUlrBgVXUAlqJQ2Q7trpSlUXZ3Vb998zktd0KkOCSi8dOPJmZb_yYGYC3zrgI3QTJHMI746LMWBZJxXhs0FByxOiwbIpNyMkknU6zvAsKW_S33fsjycZS3wh2E2hREWNYIGjgqy3YQbhLSR1Pz74P9lcGSVcnTzIUz7QLlfn9GBtwdNso30ClW8ekDfqcPPq_734MDztv0x-34vEE7thqF-619Sevd-H-l-5k_Sn8yNc5rOm_-Tnt0teUbtWfO_9sdeHmVLu-tP5HFNrLJl_44tBHI-l_rs5nekZle4j0SNWa8u364-r8uqwRJZ_Bt5Pjr0efWFd4gRku4yXDJViqMtqiUoGItOBlpJUSsbWxLNMEvQilVZyWIrSx41po6XigZGQjrU2MDstz2K7mld0HvwxUZm2gnSgdF9iG7oGJucGVlJNSRx6EPf8L02Ulp-IYF8U6nzLxr0D-FQ3_iisP3g99frY5Of5K_Zp-a9HGlQ4KXYxlgt5jIJPEg3cNBak0vtuoLjIBZ0DJsTYoDzYoURXNZnMvOkVnChYF4n-UUPww9-DN0Ew96XpbZecrokG3kIdpGnqw14rcMLNY8oSjm-3BYS9f68H_PO0X_0b-Eh5EjYjS_tIBbC_rlX0Fd83lcraoR7Alp7J5piPY-XA8yU9HdEs2HzWq9wvFiSC-
linkProvider Springer Nature
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VAoULj_IyFGokEAdq1V6vvfYBoailatQ2ikSRInFYdtdrNVJxipM0yp_iNzLjR0Iq0VsPnHf8WPub-WZ2d2YA3uUmZ-gmCC9Hevd4lKVeyoTyeGjQUHLk6CCrmk2IXi8ZDNL-Gvxuc2HoWGVrEytDnY0MrZHvohllMaVh8s8XvzzqGkW7q20LjRoWR3Y-w5Bt_Km7j__3PWMHX073Dr2mq4BnuAgnHsYXiUpp_UX5EdMRz5hWKgqtDUWWxEiRSqswyaLAhjnXkRY595VglmltQmRjvO8tuI12XNARMjFYBHioPXHToU94qBhJk6TTpOpFyAfIkJ4f0WeZrRDhVTr4iw-vbNBWvHfw8H_7Yo_gQeNhu51aJR7Dmi024W7dc3O-CRsnzWmCJ_C9v6zbTVh1-7QzUVKJWXeUu1-n5znGKT-HmXX3UVEvqxrp4x0XicHtFmdDPaRWRSS6p0pNNYbdTnE2z0r0DJ7CtxuZ5DNYL0aFfQFu5qvUWl_nUZbzCMfQJTIhNxg95kJo5kDQ_nlpmkrs1BDkXC5rSBNaJKJFVmiRMwc-Lq65qOuQXCu9TYCSdS7twojJjojRY_ZFHDvwoZIgM4bPNqrJxsAZUEGwFcmtFUk0P2Z1uEWfbMzfWC6h58DbxTBdSUf6Cjuakgy6wjxIksCB5zXYFzMLBY85hhYO7LToX97839N-ef27bMO9w9OTY3nc7R29gvusUkZaT9uC9Uk5ta_hjrmcDMflm0qtXfhx01rxB156gis
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VAhUXHuVRQ6FGAnGgVp312msfEIoaIqLSyBIgVeJgdte7aqTWKU7SKH-NX8eMHwmpRG89cN7xY-1v5pvZ3ZkBeGO1ZegmCM8ivXs8zBMvYUJ6PNBoKDlydCevmk2I4TA-OUnSDfjd5sLQscrWJlaGOh9rWiM_QDPKIkrD5Ae2ORaR9vofL3551EGKdlrbdho1RI7MYo7h2-TDoIf_-i1j_U_fDj97TYcBT3MRTD2MNWKZ0FqM9EOmQp4zJWUYGBOIPI6QLqWSQZyHHRNYrkIlLPelYIYppQNkZrzvLbgteFQZhWORLllA-FHTrU94qCRxk7DTpO2FyA3Ilp4f0iear5HiVWr4ixuvbNZWHNh_8D9_vYdwv_G83W6tKo9gwxTbcLfuxbnYhq3j5pTBY_iRrup5E4bdlHYsSio9646t-3V2ZjF-OR_lxu2hAl9WtdMn-y4ShjsoTkdqRC2MSPRQlopqD7vd4nSRl-gxPIHvNzLJp7BZjAuzA27uy8QYX9kwtzzEMXSVdMA1RpVWCMUc6LQoyHRToZ0ahZxlq9rShJwMkZNVyMnmDrxfXnNR1ye5VnqPwJXVObZL45Z1RYSetC-iyIF3lQSZN3y2lk2WBs6ACoWtSe6uSaJZ0uvDLRKzxixOshUMHXi9HKYr6ahfYcYzkkEXmXfiuOPAsxr4y5kFqGkcQw4H9ltNWN3839N-fv277MEWKkP2ZTA8egH3WKWXtMy2C5vTcmZewh19OR1NyleVhrvw86aV4g_nT4r6
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacological+Properties+of+Sulfonamide+Derivatives%2C+New+Inhibitors+of+Carbonic+Anhydrase&rft.jtitle=Bulletin+of+experimental+biology+and+medicine&rft.au=Khokhlov%2C+A+L&rft.au=Shetnev%2C+A+A&rft.au=Korsakov%2C+M+K&rft.au=Fedorov%2C+V+N&rft.date=2023-06-01&rft.issn=1573-8221&rft.eissn=1573-8221&rft.volume=175&rft.issue=2&rft.spage=205&rft_id=info:doi/10.1007%2Fs10517-023-05835-w&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-4888&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-4888&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-4888&client=summon